Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Investing

Acceleration of RAD204 Phase 1 dose escalation trial

by admin May 12, 2025
May 12, 2025
Acceleration of RAD204 Phase 1 dose escalation trial

Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial

Download the PDF here.

This post appeared first on investingnews.com

previous post
Fortnite applies to launch on Apple’s App Store after Epic Games court win
next post
Excellent Gold Intersections Verified at Kiimala Project

Related Posts

Further broad intercepts of high-grade gold at Jasper...

February 5, 2025

Top 4 Vanadium-producing Countries

May 30, 2025

Oil Price and Inflation: What’s the Correlation?

May 15, 2025

Cardiex Completes Placement & Launches Entitlement Offer

May 30, 2025

Granted Trollberget Licence Doubling Landholding

February 4, 2025

Nuvau Minerals Inc. Changes Financial Year-End

March 1, 2025

CDX May Investor Presentation

May 30, 2025

CEO Appointment

May 19, 2025

Lodgement of CONNEQT Pulse Device with the TGA

May 6, 2025

Web3 Leaders Gather in Toronto for Canada Crypto...

May 13, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 5

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved